Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
21.45
-0.34 (-1.56%)
Mar 19, 2026, 12:53 PM EDT - Market open
Sutro Biopharma Employees
Sutro Biopharma had 178 employees as of September 30, 2025. The number of employees decreased by 128 or -41.83% compared to the same quarter last year.
Employees
178
Change
-128
Growth
-41.83%
Revenue / Employee
$593,517
Profits / Employee
-$1,217,792
Market Cap
182.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 178 | -128 | -41.83% |
| Jun 30, 2025 | 244 | -60 | -19.74% |
| Mar 31, 2025 | 269 | -31 | -10.33% |
| Dec 31, 2024 | 310 | 8 | 2.65% |
| Sep 30, 2024 | 306 | 8 | 2.68% |
| Jun 30, 2024 | 304 | 7 | 2.36% |
| Mar 31, 2024 | 300 | 8 | 2.74% |
| Dec 31, 2023 | 302 | 24 | 8.63% |
| Sep 30, 2023 | 298 | 39 | 15.06% |
| Jun 30, 2023 | 297 | 55 | 22.73% |
| Mar 31, 2023 | 292 | 58 | 24.79% |
| Dec 31, 2022 | 278 | 54 | 24.11% |
| Sep 30, 2022 | 259 | 41 | 18.81% |
| Jun 30, 2022 | 242 | 38 | 18.63% |
| Mar 31, 2022 | 234 | 39 | 20.00% |
| Dec 31, 2021 | 224 | 33 | 17.28% |
| Sep 30, 2021 | 218 | 36 | 19.78% |
| Jun 30, 2021 | 204 | 27 | 15.25% |
| Mar 31, 2021 | 195 | 18 | 10.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Zentalis Pharmaceuticals | 166 |
| Cibus | 159 |
| Adagene | 138 |
| Tenaya Therapeutics | 97 |
| Cartesian Therapeutics | 75 |
| SAB Biotherapeutics | 63 |
| Acumen Pharmaceuticals | 61 |
STRO News
- 6 days ago - Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 - Seeking Alpha
- 22 days ago - Sutro Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering - GlobeNewsWire
- 2 months ago - Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 months ago - Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript - Seeking Alpha
- 4 months ago - Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025 - GlobeNewsWire
- 4 months ago - Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - GlobeNewsWire